|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.South Korea |
First Approval Date01 May 2008 |
|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.
Clinical study to demonstrate an at least equivalent performance of a new PET molecular Imaging radiopharmaceutical named [18F] LBT-999 in brain imaging compared to the SPECT reference method named [123I]-FP-CIT to establish the differential diagnosis between Parkinson's Disease and Essential Tremor.
100 Clinical Results associated with Zionexa SAS
0 Patents (Medical) associated with Zionexa SAS
100 Deals associated with Zionexa SAS
100 Translational Medicine associated with Zionexa SAS